References:
1. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
2. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
3. Pagano L and Mayor S. Future Sci OA. 2018;4(6):FSO307.
4. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
5. Góralska K et al. Infection. 2018;46(4):443–459.
6. Rüping MJGT et al. Drugs. 2008;68(14):1941–1962.
7. Pagano L et al. Blood Rev. 2017;31(2):17–29.
8. Kuse E-R et al. Lancet. 2007;369(9572):1519–1527.
9. De Pascale G et al. Curr Opin Crit Care. 2015;21(5):421–429.
10. Fung M et al. Clin Infect Dis. 2018;67(7):1142–1143.
11. AmBisome® Summary of Product Characteristics (UK).
Available at: https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
12. Lass-Flörl C and Cuenca-Estrella M. J Antimicrob Chemother.
2017;46(1):62–68.
13. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
14. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
15. Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30(1):51–83.
16. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
17. Manavathu EK et al. J Antimicrob Chemother. 2000;46(2):229–234.
18. Messer SA et al. Diagnos Microbiol Infect Dis. 2020;97(1):115007.
19. Mesa-Arango AC et al. Front Microbiol. 2012;3:286.
20. Vallejo C et al. Rev Esp Quimioter. 2013;26(4):378–386.
21. Vincent BM et al. PLoS Biol. 2013;11(10):e1001692.
22. Science M et al. Pediatr Blood Cancer. 2020;67(4):e28145.
23. Agrawal S et al. J Antimicrob Chemother. 2016;71(Suppl 2):ii37–ii42.
24. Cornely OA et al. Mycoses. 2019:62(9):716–729.
25. Oh J et al. Mycoses. 2020;63(1):89–94.
References:
1. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
14. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
15. Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30(1):51–83.
16. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
17. Manavathu EK et al. J Antimicrob Chemother. 2000;46(2):229–234.
18. Messer SA et al. Diagnos Microbiol Infect Dis. 2020;97(1):115007.
19. Mesa-Arango AC et al. Front Microbiol. 2012;3:286.
20. Vallejo C et al. Rev Esp Quimioter. 2013;26(4):378–386.
21. Vincent BM et al. PLoS Biol. 2013;11(10):e1001692.
22. Science M et al. Pediatr Blood Cancer. 2020;67(4):e28145.
23. Agrawal S et al. J Antimicrob Chemother. 2016;71(Suppl 2):ii37–ii42.
24. Cornely OA et al. Mycoses. 2019:62(9):716–729.
25. Oh J et al. Mycoses. 2020;63(1):89–94.
2. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
3. Pagano L and Mayor S. Future Sci OA. 2018;4(6):FSO307.
4. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
5. Góralska K et al. Infection. 2018;46(4):443–459.
6. Rüping MJGT et al. Drugs. 2008;68(14):1941–1962.
7. Pagano L et al. Blood Rev. 2017;31(2):17–29.
8. Kuse E-R et al. Lancet. 2007;369(9572):1519–1527.
9. De Pascale G et al. Curr Opin Crit Care. 2015;21(5):421–429.
10. Fung M et al. Clin Infect Dis. 2018;67(7):1142–1143.
11. AmBisome® Summary of Product Characteristics (UK).
Available at: https://www.medicines.org.uk/emc/product/1022/smpc#gref.
[Last accessed: March 2023].
12. Lass-Flörl C and Cuenca-Estrella M. J Antimicrob Chemother. 2017;46(1):62–68.
13. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
This educational tool is developed and fully funded by Gilead Sciences, and it is intended for healthcare
professionals only. It contains information about Gilead products, educational materials on therapy areas,
and professional resources.
Prescribing information for Liposomal Amphotericin B